WO2002007736A1 - The process for manufacturing of clear liquid pharmaceutical composition of azithromycin - Google Patents

The process for manufacturing of clear liquid pharmaceutical composition of azithromycin Download PDF

Info

Publication number
WO2002007736A1
WO2002007736A1 PCT/IB2001/001313 IB0101313W WO0207736A1 WO 2002007736 A1 WO2002007736 A1 WO 2002007736A1 IB 0101313 W IB0101313 W IB 0101313W WO 0207736 A1 WO0207736 A1 WO 0207736A1
Authority
WO
WIPO (PCT)
Prior art keywords
azithromycin
ph
clear liquid
solution
water
Prior art date
Application number
PCT/IB2001/001313
Other languages
French (fr)
Inventor
Bakulesh Mafatlal Khamar
Sridhar Krishnamurthy Gumudavelli
Original Assignee
Cadila Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IN687/MUM/2000 priority Critical
Priority to IN687MU2000 priority
Application filed by Cadila Pharmaceuticals Limited filed Critical Cadila Pharmaceuticals Limited
Publication of WO2002007736A1 publication Critical patent/WO2002007736A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Abstract

Azithromycin is a macrolide antibiotic used for treating infections. This is available in a solid oral dosage form. It is desirable to have a clear liquid formulaiton also for treating severe infections by intravenous administration of the drug. Currently, it is not possible to manufacture liquid preparation which is ready to use. As it is not soluble in water or other known solvents, for this purpose, it is being marketed as lyophilized preparation which is reconstituted prior to use. According to present invention, it is found that it is soluble in water at pH 5.0. The change in pH can be obtained by adding citric acid in a desired concentration. However, this solution is not stable, and precipitates are seen over the time. According to the present invention, this solution is stabilized by addition of sodium salts like sodium hydroxide, thereby changing its pH from 5.0 to 7.0. The solution so prepared remains clear and is stable for a longer period.

Description

FORM 2

THE PATENTS ACT, 1970

THE COMPLETE SPECIFICATION

(See section 10)

1. THE PROCESS FOR MANUFACTURING OF CLEAR LIQUID PHARMACEUTICAL COMPOSITION OF AZITHROMYCIN

2. Cadila Pharmaceuticals Limited, IRM House, Off CG. Road, Navrangpura, Ahmedabad- 380009, Gujarat, India, an Indian company.

3. The following specification particularly describes and ascertains the nature of this invention and the manner in which it has to be performed.

FIELD OF INVENTION

The objective of present invention is to manufacture clear liquid pharmaceutical composition of Azithromycin.

BACKGROUND OF THE INVENTION

Azithromycin is the U.S.A.N. (generic name) for 9a~aza-9a-methyl-9-deoxo-9a- homoerythromycin A, a broad spectrum antimicrobial compound derived from erythromycin A. Azithromycin was independently discovered by Bright, U.S. Pat. No. 4,474,768 and Kobrehel et al., U.S. Pat. No. 4,517,359. These patents disclose that azithromycin and certain derivatives thereof possess antibacterial properties and are accordingly useful as antibiotics.

Azithromycin is a macrolide antibiotic used for treating infections. This is available in a solid oral dosage form and for intravenous use as, lyophilized powder. It is desirable to have a clear liquid formulation also for treating severe infections by intravenous administration of the drug.

Currently, it is not possible to manufacture liquid preparation which is ready to use. As it is not soluble in water or other known solvents, for this purpose, it is being marketed as lyophilized preparation which is reconstituted prior to use.

REFERENCES:

U.S. patent no. 4474768

N- ethyl 11-aza-10- eoxo-10-dihydro-erytromycin A, intermediates therefore.

Bright; Gene M

Pfizer Inc. U.S. patent no. 4517359

11 -Methyl-11 -aza-4-0-cladinosyl-6-0-desosaminyl-15-ethyl-7, 13, 14- trihydroxy-3,5,7,9,12,14-hexamethyl-oxacyclopentadecane-2-one and derivatives thereof.

Kobrehel; Gabrijela; Djokic; Slobodan

Sour Pliva farmaceutska, kemijska prehrambena i kozmeticka industrija

SUMMARY OF THE INVENTION

The present invention describes a method for preparing clear liquid pharmaceutical composition of Azithromycin. This is made possible by solubilizing azithromycin in water at pH 4.0 to 6.0 and then adding sodium hydroxide, thereby changing the pH between 6.0 to 7.0.

Azithromycin liquid so prepared as per the invention remains clear and was found to be stable for longer period.

DESCRIPTION OF THE INVENTION

According to the present invention is described a method of preparing clear liquid pharmaceutical composition of Azithromycin.

The objective of the present invention is to provide azithromycin as a liquid preparation which is stable and can be ready to use.

According to present invention it is found that azithromycin is soluble in water at pH between 4.0 to 6.0.

It is also found that azithromycin is soluble in other solvents like polyalcohols which comprises of propylene glycol, glycerine, polyethylene glycol and sorbitol. However when a solution is prepared using azithromycin at pH between 4.0 to 6.0, it does not remain stable for a long term and develops precipitation. Thus, the pharmaceutical composition prepared is not stable.

It is further observed as per the present invention that when pH is raised further, then azithromycin remains in solution and product is also stable for a longer time.

EXAMPLE 1 :

Figure imgf000005_0001

1. Citric acid anhydrous is dissolved in 200 ml Water for injection.

2. The pH of the above solution is adjusted to 4.0 to 6.0 with Sodium hydroxide.

3. Azithromycin is added to this solution and mixed.

4. Now Sodium hydroxide solution is added till clear solution is added, and the pH is between 6.0 to 7.0.

5. The solution is filtered through 0.22 micron membrane and filled in vials.

6. The vials are then sterlized by autoclaving at 120°C with 15 LB pressure for 20 minutes.

EXAMPLE 2:

Solvents which can be used for the preparation of liquid formulation of Azithromycin are:

1. Water

2. Polyalcohol: a) Propylene glycol b) Polyethylene glycol c) glycerine d) Sorbitol

The preparation so prepared as per the present invention can be used for administration through oral or parenteral route.

Claims

We claim:
1. The process of manufacturing clear liquid pharmaceutical composition of Azithromycin, comprises the steps of: a) Adding azithromycin to solvent with appropriate pH. b) Mixing of above preparation to obtain clear liquid preparation.
2. The clear liquid preparation of azithromycin as claimed in claim 1 is further stabilized by bringing pH from 5.5 to 7.0.
3. The solvent as claimed in claim 1 is water.
4. The solvent as claimed in claim 1 is a polyalcohol like propylene glycol, glycerine, polyethylene glycol and the like.
5. The solvent as claimed in claim 1 and 4 is selected from propylene glycol, glycerine, polyethylene glycol, sorbitol and the like.
6. The solvent as claimed in claim 1 is made up of single ingredient or a combination of them.
7. The pH as claimed in claim 1 is between 4.0 to 6.0.
8. The process as described in claim 1 and as described in examples 1 and 2.
PCT/IB2001/001313 2000-07-24 2001-07-23 The process for manufacturing of clear liquid pharmaceutical composition of azithromycin WO2002007736A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IN687/MUM/2000 2000-07-24
IN687MU2000 2000-07-24

Publications (1)

Publication Number Publication Date
WO2002007736A1 true WO2002007736A1 (en) 2002-01-31

Family

ID=11097267

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2001/001313 WO2002007736A1 (en) 2000-07-24 2001-07-23 The process for manufacturing of clear liquid pharmaceutical composition of azithromycin

Country Status (1)

Country Link
WO (1) WO2002007736A1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1381601A1 (en) * 2001-04-25 2004-01-21 Hanmi Pharm. Co., Ltd. Clathrate of azithromycin hydrate with 1,2-propyleneglycol, method for the manufacture thereof and pharmaceutical composition comprising same
ES2220229A1 (en) * 2003-05-29 2004-12-01 Quimica Sintetica, S.A. Addition salts of azitromycin and citric acid and procedure for obtaining it.
US6861413B2 (en) 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
US6977243B2 (en) 2001-05-22 2005-12-20 Pfizer Inc. Crystal forms of azithromycin
ES2289911A1 (en) * 2003-05-29 2008-02-01 Quimica Sintetica, S.A. New addition salt of azithromycin and citric acid useful for the treatment of infection caused by bacteria or protozoans contains specific molar ratio of azithromycin and citric acid
US8106111B2 (en) 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
CN102552918A (en) * 2012-02-02 2012-07-11 山东齐都药业有限公司 Stabilizer of lyophilized powder injection for azithromycin injection
CN102755287A (en) * 2012-07-20 2012-10-31 天津药业集团新郑股份有限公司 Azithromycin oral liquid and preparation method thereof
EP3307275A4 (en) * 2015-06-10 2019-01-09 Piedmont Animal Health, LLC Injectable antibiotic formulations and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307128A2 (en) * 1987-09-10 1989-03-15 Pfizer Inc. Azithromycin and derivatives as antiprotozoal agents
WO2000057866A2 (en) * 1999-03-31 2000-10-05 Insite Vision Incorporated Use of azalide antibiotics for the topical treatment or prevention of ocular infections
EP1075837A2 (en) * 1999-08-09 2001-02-14 S.I.F.I. Società Industria Farmaceutica Italiana S.p.A. Process for the preparation of aqueous formulations for ophthalmic use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307128A2 (en) * 1987-09-10 1989-03-15 Pfizer Inc. Azithromycin and derivatives as antiprotozoal agents
WO2000057866A2 (en) * 1999-03-31 2000-10-05 Insite Vision Incorporated Use of azalide antibiotics for the topical treatment or prevention of ocular infections
EP1075837A2 (en) * 1999-08-09 2001-02-14 S.I.F.I. Società Industria Farmaceutica Italiana S.p.A. Process for the preparation of aqueous formulations for ophthalmic use

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002253698B2 (en) * 2001-04-25 2005-12-08 Hanmi Pharm. Co., Ltd. Clathrate of azithromycin hydrate with 1,2-propyleneglycol, method for the manufacture thereof and pharmaceutical composition comprising same
EP1381601A4 (en) * 2001-04-25 2004-06-16 Hanmi Pharm Ind Co Ltd Clathrate of azithromycin hydrate with 1,2-propyleneglycol, method for the manufacture thereof and pharmaceutical composition comprising same
US7205394B2 (en) 2001-04-25 2007-04-17 Hanmi Pharm. Co., Ltd. Clathrate of azithromycin hydrate with 1,2-propyleneglycol, method for the manufacture thereof and pharmaceutical composition comprising same
EP1381601A1 (en) * 2001-04-25 2004-01-21 Hanmi Pharm. Co., Ltd. Clathrate of azithromycin hydrate with 1,2-propyleneglycol, method for the manufacture thereof and pharmaceutical composition comprising same
US7282486B2 (en) 2001-05-22 2007-10-16 Pfizer Inc Crystal forms of azithromycin
US7309782B2 (en) 2001-05-22 2007-12-18 Pfizer Inc. Crystal forms of azithromycin
US6977243B2 (en) 2001-05-22 2005-12-20 Pfizer Inc. Crystal forms of azithromycin
US7053192B2 (en) 2001-05-22 2006-05-30 Pfizer Inc. Crystal forms of azithromycin
US7081525B2 (en) 2001-05-22 2006-07-25 Pfizer Inc. Crystal forms of azithromycin
US7105179B2 (en) 2001-05-22 2006-09-12 Pfizer Inc. Crystal forms of azithromycin
US7307156B2 (en) 2001-05-22 2007-12-11 Pfizer Inc. Crystal forms of azithromycin
US6861413B2 (en) 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
ES2220229A1 (en) * 2003-05-29 2004-12-01 Quimica Sintetica, S.A. Addition salts of azitromycin and citric acid and procedure for obtaining it.
WO2004106355A1 (en) * 2003-05-29 2004-12-09 Quimica Sintetica, S.A. Addition salts of azithromycin and citric acid and process for preparing them
ES2289911A1 (en) * 2003-05-29 2008-02-01 Quimica Sintetica, S.A. New addition salt of azithromycin and citric acid useful for the treatment of infection caused by bacteria or protozoans contains specific molar ratio of azithromycin and citric acid
CN100415764C (en) * 2003-05-29 2008-09-03 新特提卡化学股份有限公司 Addition salts of azithromycin and citric acid and process for preparing them
US8106111B2 (en) 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
CN102552918A (en) * 2012-02-02 2012-07-11 山东齐都药业有限公司 Stabilizer of lyophilized powder injection for azithromycin injection
CN102755287A (en) * 2012-07-20 2012-10-31 天津药业集团新郑股份有限公司 Azithromycin oral liquid and preparation method thereof
EP3307275A4 (en) * 2015-06-10 2019-01-09 Piedmont Animal Health, LLC Injectable antibiotic formulations and use thereof
US10286003B2 (en) 2015-06-10 2019-05-14 Piedmont Animal Health, Llc Injectable antibiotic formulations and use thereof

Similar Documents

Publication Publication Date Title
DE60003586T2 (en) Antibiotic azalide compositions
AU2002352105B2 (en) Platinum derivative pharmaceutical formulations
Evans Tulathromycin: An overview of a new triamilide antimicrobial for livestock respiratory disease
JP4689959B2 (en) Formulations containing cephalosporin compounds and their use in the treatment of bacterial infections in dogs and cats
CA2400317C (en) Improved paste formulations
Periti et al. Clinical pharmacokinetic properties of the macrolide antibiotics
US20120035352A1 (en) 6-11 Bicyclic Ketolide Derivatives
AU2009308180B2 (en) Methods for treating gastrointestinal diseases
JP2013241440A (en) Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and for production thereof
KR100567149B1 (en) Crystal form 0 of clarithromycin
KR101052705B1 (en) Aqueous formulations containing aminoglycoside antibiotics and bromfenac
US4329453A (en) Cephalosporin antibiotic
KR100486053B1 (en) Novel Erythromycin Derivatives, Method for Preparing Same, and Use Thereof as Drugs
CA2071623C (en) Cyclodextrin composition
EP0091782B1 (en) Inclusion compound of lankacidin-group antibiotic and use thereof
ES2665033T3 (en) Liposome that has an internal aqueous phase containing sulfobutyl ether cyclodextrin salt
US2736725A (en) Complexes of tetracycline antibiotics and preparation of same
DE60208784T2 (en) Clathrate of azithromycin hydrate with 1,2-propylene glycol, process for the production thereof and pharmaceutical composition containing thereof
US5958888A (en) Water miscible macrolide solutions
EP2062582B1 (en) Antibiotic composition comprising beta-lactam antibiotics, aminoglycosides and buffers
US7265094B2 (en) 9N-substituted 6-11 bicyclic erythromycin derivatives
EP0986403A1 (en) Polar drug or prodrug compositions with extended shelf-life storage and a method of making thereof
CZ79296A3 (en) Water soluble nimesulfide salt, aqueous solution thereof and pharmaceutical composition containing thereof, process for preparing such salt combination based on nimesulfide, pharmaceutical composition containing thereof and the use of the salt combination
EP1962794A2 (en) Long acting injectable parasiticidal formulations
CN1476335A (en) Freeze-dried pantoprazole preparation and pantoprazole injection

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase